1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]

  • April 2018
  • ID: 5438887
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Established brands, generics, biologics and new MOAs fight for supremacy in the COPD treatment landscape

Established treatments are coming under pressure from generics, new combinations, biologics and new MOAs as the COPD treatment landscape continues to evolve. Of the key companies currently competing in this space -- AstraZeneca, Boehringer Ingelheim, GSK and Novartis -- which companies do key opinion leaders (KOLs) think will take the spoils? More importantly, how can smaller companies which are offering new treatment options (e.g. Chiesi’s Trimbow, one of the first closed triple ICS/LABA/LAMA combination therapies approved in Europe) carve themselves out a niche?

KOLs also offer fresh insight on the continued development of biologic treatment options (e.g. anti-IL-4 and anti-IL-5 mAbs from Sanofi/Regeneron, AstraZeneca and GSK), as well as their updated views on several next-generation therapies and new mechanisms of action, including gene therapies, vaccines and others. Twelve of the world’s leading KOLs offer their candid insights on these issues and more.

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• Is it all change in the COPD treatment paradigm? Three products continue to dominate the COPD treatment landscape, so how quickly will these products lose ground to the newer single and combination therapies, and generics, entering the market?
• What impact have updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines had on treatment practice? New guidelines on COPD patient assessment, segmentation and treatment were published in 2017, so what has been the ‘real-world’ impact and which companies have benefited'B3
• Are fixed-dose triple combination therapies the answer to remaining clinical unmet needs? With the approval of two ICS/LABA/LAMA combos -- Trelegy Ellipta from GSK and Trimbow from Chiesi -- how do KOLs expect these to be used in clinical practice; will they improve clinical outcomes, and are there any lingering concerns?
• Seretide/Advair generics are here, but what impact will they have in the treatment of COPD? Generic versions of GSK’s Seretide/Advair are expected to penetrate the market in the near term. Will the potential for lowering the costs of therapy win the argument, or has treatment guidance changed before their impact can be felt?
• Will biologics find a niche in the management of COPD? Development of anti-IL-5 mAbs from GSK (mepolizumab) and AstraZeneca (benralizumab), and an anti-IL-4 mAb from Sanofi/Regeneron (dupilumab), continues but what does the future hold? Are KOLs optimistic or will biologics fail to breathe new life into the COPD treatment landscape?
• Do KOLs think any of the new MOAs in development warrant excitement? New MOAs range from vaccines, gene therapies, and novel combinations, but do any of them ignite excitement with the KOLs? If so, which ones and how could they fare?

Quotes

“I think dual bronchodilators have become the gold standard. Most of my patients are on dual bronchodilators alone or with something else. I would say that this is the centre or the baseline of the therapy, according to the guidelines, but it is only guidance.” EU Key Opinion Leader

“I’m very enthusiastic about this. We have vaccinations for some types of streptococcus pneumonia and I frequently recommend these to patients, but there are many other causes of infection in healthy people as well as COPD.” US Key Opinion Leader

Sample of therapies covered
Marketed Therapies

LAMA monotherapies
• Spiriva (tiotropium; Boehringer Ingelheim)
• Seebri (glycopyrronium; Novartis)
• Eklira/Tudorza (aclidinium; AstraZeneca/Takeda)
• Incruse (umeclidinium; GSK)
• Arcapta/Onbrez (indacaterol; Novartis)
• Striverdi (olodaterol; Boehringer Ingelheim)

LAMA/LABA combinations
• Stiolto/Spiolto (tiotropium/olodaterol; Boehringer Ingelheim)
• Ultibro/Utibron (glycopyrronium/indacaterol; Novartis)
• Eklira/Tudorza (aclidinium; AstraZeneca/Takeda)
• Anoro (umeclidinium/vilanterol; GSK)
• Bevespi (glycopyrronium/formoterol; AstraZeneca)

ICS/LABA combinations
• Seretide/Advair (fluticasone propionate/salmeterol; GSK)
• Relvar Ellipta/Breo Ellipta (fluticasone furoate/vilanterol; GSK)
• Symbicort (budesonide/formoterol; AstraZeneca)

ICS/LABA/LAMA triple combinations
• Trelegy Ellipta (fluticasone furoate/vilanterol/umeclidinium; GSK)
• Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi)

Pipeline Programmes
• budesonide/formoterol (PT009; AstraZeneca)
• budesonide/formoterol /glycopyrrolate (PT010; AstraZeneca)
• benralizumab (Fasenra; AstraZeneca)
• Mepolizumab (Nucala; GSK)
• Revefenacin (Theravance/Mylan)
• GSK3277511A (GSK)
• SB010 (Sternal Biologicals)
• Batefenterol (GSK)
• BCT197 (Mereo Biopharma)
• Nemiralisib (GSK)
• Danirixin (GSK)
• RPL554 (Verona)

KOLs interviewed

KOLs from North America
• Roger Abrahams. President, Morgantown Pulmonary Associates, Morgantown, WV, USA
• Richard Casaburi. Professor and Chief, Division of Respiratory and Critical Care Physiology and Medicine, Harbor at the University of California at Los Angeles Medical Center, CA, USA
• Donald A. Mahler. Emeritus Professor of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
• Donald Tashkin. Emeritus Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), CA, USA
• Robert (Bob) Wise. Director of Research, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical School, Baltimore, MD, USA
• Anonymous US KOL. Professor of Medicine, and former Chief, Division of Pulmonary Diseases and Critical Care Medicine, at a leading respiratory hospital in the US

KOLs from Europe
• Leif Hilding Bjermer. Professor of Pulmonary Medicine, Department of Respiratory Medicine and Allergology, Lund University, Sweden
• Marc Miravitlles. Chest Physician and Senior Researcher, Department of Pneumology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
• David Singh. Professor of Clinical Pharmacology and Respiratory Medicine, University Hospital Of South Manchester NHS Foundation Trust, Manchester, UK
• Jadwiga Wedzicha. Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College, London, UK
• Anonymous German KOL. Professor and leading pulmonologist focused on COPD, asthma and general pulmonary medicine at a leading German teaching hospital
• Anonymous German KOL. Professor and specialist in internal medicine, pulmonology, allergology and sleep medicine at a leading German teaching hospital

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Intermittent Claudication - Pipeline Review, H1 2020

Intermittent Claudication - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Intermittent Claudication - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication - Pipeline Review, H1 2020, provides an overview of ...

Myasthenia Gravis - Pipeline Review, H1 2020

Myasthenia Gravis - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Myasthenia Gravis - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2020, provides an overview of the Myasthenia Gravis ...

Birch Pollen Allergy - Pipeline Review, H1 2020

Birch Pollen Allergy - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Birch Pollen Allergy - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy - Pipeline Review, H1 2020, provides an overview of the Birch ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on